Immuron Share Price - IMRN

Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
CHART Trader
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Immuron Ltd IMRN NASDAQ Depository Receipt
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 3.8682 0.00 0.00 0.00 3.8682 09:29:40
Bid Price Ask Price Spread Spread % News
3.75 4.14 0.39 9.42% - -
Last Trade Time Type Quantity Stock Price Currency
- 0  0.00 USD

Immuron Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio
 17.10M 4.42M  -3.01M -0.90 - 4.42M
Dividends Per Share Dividend Yield
-  - 0.00% - -

more financials information »

News Immuron

Date Time Source Heading
11/21/201907:00GlobeNewswire Inc.Immuron Plans Phase 3 trial for IMM-124E to Prevent..
11/21/201906:05Edgar (US Regulatory)Report of Foreign Issuer (6-k)
11/06/201906:12Edgar (US Regulatory)Report of Foreign Issuer (6-k)
11/06/201906:09Edgar (US Regulatory)Report of Foreign Issuer (6-k)
11/04/201911:30GlobeNewswire Inc.Immuron Receives AUD $0.53M R&D Tax Concession Refund
11/04/201906:16Edgar (US Regulatory)Report of Foreign Issuer (6-k)
10/29/201906:05Edgar (US Regulatory)Report of Foreign Issuer (6-k)

Latest IMRN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

IMRN Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191212 15:03:05